Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
ලංකාවේ හොඳම උපකාරක පන්ති සහ ගුරුවරුන් එකම තැනකින් - TopTuition.lk
dulithapathum
Updated:
Today at 8:07 AM
Colombo
RidhMathraa ’26 🎶✨
Tmadhusanka
Updated:
Wednesday at 11:58 PM
Ad icon
Colombo
PXN V10 Pro Direct Drive Racing Wheel (Under Warranty)
Abdur Rahman
Updated:
Wednesday at 10:23 PM
Ad icon
USDT ණය සේවාව - USDT Loan Service
පුරවැසියා
Updated:
Wednesday at 4:54 PM
Ad icon
🎮 INDIAN PSN GIFT CARDS AVAILABLE NOW! 🎮
madukaperera
Updated:
Tuesday at 12:57 PM
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
ElaKiri Talk!
Gene test helps many breast cancer patients avoid chemotherapy
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 31433437" data-attributes="member: 562115"><p>Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found.</p><p></p><p>The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) was designed to reduce the use of unnecessary chemotherapy for people with newly diagnosed breast cancer. It followed more than 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand.</p><p></p><p>Chief Investigator of the OPTIMA trial and Professor of Breast Oncology at the UCL Cancer Institute, Professor Rob Stein said: "OPTIMA addresses a long-standing challenge in breast cancer care: identifying who truly benefits from chemotherapy and who does not. Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes.</p><p></p><p>This genomic test from Veracyte is called Prosigna, which measures the activity of genes involved in breast cancer growth.</p><p></p><p>The independent study enrolled 4,429 women and men aged ≥40 years with ER-positive HER2-negative early breast cancer and 0–9 involved axillary lymph nodes.</p><p>Of the 4,429 people who took part in the trial, more than two-thirds (68%) had a low Prosigna score.</p><p></p><p>For this group, <strong>the results showed that outcomes were very similar whether chemotherapy was given or not. Five years after treatment:</strong></p><ul> <li data-xf-list-type="ul">94.8% of those who received chemotherapy alongside hormone therapy were alive and free from breast cancer recurrence</li> <li data-xf-list-type="ul">93.6% of those treated with hormone therapy alone were also alive and recurrence-free</li> </ul><p>A statistical test showed that at the most, only 2% of patients with a low Prosigna score treated with chemotherapy will benefit from this treatment.</p><p></p><p><strong>This suggests that for patients with low Prosigna scores, chemotherapy offers little or no additional benefit, meaning many people could safely avoid it and its side effects.</strong></p></blockquote><p></p>
[QUOTE="imhotep, post: 31433437, member: 562115"] Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found. The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) was designed to reduce the use of unnecessary chemotherapy for people with newly diagnosed breast cancer. It followed more than 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Chief Investigator of the OPTIMA trial and Professor of Breast Oncology at the UCL Cancer Institute, Professor Rob Stein said: "OPTIMA addresses a long-standing challenge in breast cancer care: identifying who truly benefits from chemotherapy and who does not. Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes. This genomic test from Veracyte is called Prosigna, which measures the activity of genes involved in breast cancer growth. The independent study enrolled 4,429 women and men aged ≥40 years with ER-positive HER2-negative early breast cancer and 0–9 involved axillary lymph nodes. Of the 4,429 people who took part in the trial, more than two-thirds (68%) had a low Prosigna score. For this group, [B]the results showed that outcomes were very similar whether chemotherapy was given or not. Five years after treatment:[/B] [LIST] [*]94.8% of those who received chemotherapy alongside hormone therapy were alive and free from breast cancer recurrence [*]93.6% of those treated with hormone therapy alone were also alive and recurrence-free [/LIST] A statistical test showed that at the most, only 2% of patients with a low Prosigna score treated with chemotherapy will benefit from this treatment. [B]This suggests that for patients with low Prosigna scores, chemotherapy offers little or no additional benefit, meaning many people could safely avoid it and its side effects.[/B] [/QUOTE]
Insert quotes…
Verification
Hathara warak wissa keeyada? (Hathara wadi karanna 20)
Post reply
Top
Bottom